search
Back to results

TELI COM - Telithromycin in Children With Otitis Media

Primary Purpose

Otitis Media, Suppurative, Otitis Media, Purulent

Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Telithromycin
Azithromycin
Sponsored by
Sanofi
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Otitis Media, Suppurative focused on measuring Otitis Media, Suppurative, Purulent, Ketolide, Azithromycin, Telithromycin, Controlled Clinical Trials

Eligibility Criteria

6 Months - 6 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subjects meeting all of the following criteria will be considered for enrollment into the study: Subjects ≥6 months and <72 months (< 6 years) of age; Recent (within the last 72 hours) and rapid onset of AOM symptoms and signs; The presence of MEF on otoscopy indicated by a bulging tympanic membrane; Otalgia or ear tugging or touching within the last 24 hours that interferes with or precludes normal activity or sleep; At least 1 of the following clinical findings not specific to AOM: fever, vomiting, diarrhea, anorexia, sleep disturbance, or irritability; Caregiver-reported AOM symptoms sufficient for entry according to protocol criteria. Caregiver-reported AOM symptoms diary Tympanometry exhibiting: Type B curve or positive pressure peak curves. Exclusion Criteria: Subjects presenting with any of the following will not be included in the study: Uncertain diagnosis of AOM or mild to moderate symptoms and signs of AOM that would make the subject a candidate for observation and analgesic therapy with observation for 2-3 days. Otorrhea or tympanostomy tube present in the ear to be evaluated; Otitis externa; Down syndrome, cleft palate, craniofacial disorders, cystic fibrosis/mucoviscidosis, immotile cilia syndrome, congenital immunodeficiency or acquired immunodeficiency syndrome with <25% CD4 count or requiring prophylaxis for Pneumocystis jiroveci (carinii) or requiring treatment for an opportunistic infection; Known congenital long QT syndrome; Known or suspected uncorrected hypokalemia (≤3 mmol/L [mEq/L]), hypomagnesemia, bradycardia (<50 bpm); Myasthenia gravis; Known impaired renal function, as shown by creatinine clearance ≤25 mL/min; History of hypersensitivity or intolerance to macrolides or azithromycin; Previous enrollment in this study or previous treatment with telithromycin; Children of the investigator or subinvestigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the protocol.

Sites / Locations

  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis

Outcomes

Primary Outcome Measures

The primary efficacy variables will be time to symptom resolution (TSR) and clinical cure at theposttherapy/TOC Visit 3.

Secondary Outcome Measures

Adverse events (AEs) reported by subjects, their parents/legally authorized representative, orobserved by the investigators will be recorded throughout the study.

Full Information

First Posted
April 13, 2006
Last Updated
April 2, 2009
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT00315003
Brief Title
TELI COM - Telithromycin in Children With Otitis Media
Official Title
Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 mg/kg od for 4 Days, in Children With Acute Otitis Media
Study Type
Interventional

2. Study Status

Record Verification Date
April 2009
Overall Recruitment Status
Terminated
Why Stopped
Pediatric development program terminated by sponsor
Study Start Date
January 2006 (undefined)
Primary Completion Date
July 2006 (Actual)
Study Completion Date
July 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Sanofi

4. Oversight

5. Study Description

Brief Summary
This is a multinational, randomized (1:1), double-blind, double-dummy, comparative, 2- treatmentgroup study in children (age range: ≥6 months and <72 months [< 6 years of age]) with AOM.Subjects will be randomized to receive either telithromycin (50 mg/mL) oral suspension 25 mg/kgonce daily for 5 days or azithromycin (40 mg/mL) oral suspension (10 mg/kg once on Day 1, followed by 5 mg/kg once daily on Days 2-5, not to exceed 500 mg onDay 1 and 250 mg/day from Days 2 - 5. Matching placebo suspensions for telithromycin and azithromycin will also be dispensed to provide blinding for the different treatment regimens.Assessments and reporting of safety will be carried out at all visits.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Otitis Media, Suppurative, Otitis Media, Purulent
Keywords
Otitis Media, Suppurative, Purulent, Ketolide, Azithromycin, Telithromycin, Controlled Clinical Trials

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
1500 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Telithromycin
Intervention Type
Drug
Intervention Name(s)
Azithromycin
Primary Outcome Measure Information:
Title
The primary efficacy variables will be time to symptom resolution (TSR) and clinical cure at theposttherapy/TOC Visit 3.
Secondary Outcome Measure Information:
Title
Adverse events (AEs) reported by subjects, their parents/legally authorized representative, orobserved by the investigators will be recorded throughout the study.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects meeting all of the following criteria will be considered for enrollment into the study: Subjects ≥6 months and <72 months (< 6 years) of age; Recent (within the last 72 hours) and rapid onset of AOM symptoms and signs; The presence of MEF on otoscopy indicated by a bulging tympanic membrane; Otalgia or ear tugging or touching within the last 24 hours that interferes with or precludes normal activity or sleep; At least 1 of the following clinical findings not specific to AOM: fever, vomiting, diarrhea, anorexia, sleep disturbance, or irritability; Caregiver-reported AOM symptoms sufficient for entry according to protocol criteria. Caregiver-reported AOM symptoms diary Tympanometry exhibiting: Type B curve or positive pressure peak curves. Exclusion Criteria: Subjects presenting with any of the following will not be included in the study: Uncertain diagnosis of AOM or mild to moderate symptoms and signs of AOM that would make the subject a candidate for observation and analgesic therapy with observation for 2-3 days. Otorrhea or tympanostomy tube present in the ear to be evaluated; Otitis externa; Down syndrome, cleft palate, craniofacial disorders, cystic fibrosis/mucoviscidosis, immotile cilia syndrome, congenital immunodeficiency or acquired immunodeficiency syndrome with <25% CD4 count or requiring prophylaxis for Pneumocystis jiroveci (carinii) or requiring treatment for an opportunistic infection; Known congenital long QT syndrome; Known or suspected uncorrected hypokalemia (≤3 mmol/L [mEq/L]), hypomagnesemia, bradycardia (<50 bpm); Myasthenia gravis; Known impaired renal function, as shown by creatinine clearance ≤25 mL/min; History of hypersensitivity or intolerance to macrolides or azithromycin; Previous enrollment in this study or previous treatment with telithromycin; Children of the investigator or subinvestigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ICD CSD
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Sanofi-Aventis
City
Bridgewater
State/Province
New Jersey
ZIP/Postal Code
08807
Country
United States
Facility Name
Sanofi-Aventis
City
Buenos Aires
ZIP/Postal Code
1642
Country
Argentina
Facility Name
Sanofi-Aventis
City
Sao Paulo
ZIP/Postal Code
05677-000
Country
Brazil
Facility Name
Sanofi-Aventis
City
Laval
Country
Canada
Facility Name
Sanofi-Aventis
City
Providencia
State/Province
Santiago
Country
Chile
Facility Name
Sanofi-Aventis
City
Santafe de Bogota
Country
Colombia
Facility Name
Sanofi-Aventis
City
San José
Country
Costa Rica
Facility Name
Sanofi-Aventis
City
Praha
ZIP/Postal Code
160 00
Country
Czech Republic
Facility Name
Sanofi-Aventis
City
Santo-Domingo
Country
Dominican Republic
Facility Name
Sanofi-Aventis
City
Guatemala
Country
Guatemala
Facility Name
Sanofi-Aventis
City
Israel
Country
Israel
Facility Name
Sanofi-Aventis
City
Panama
Country
Panama
Facility Name
Sanofi-Aventis
City
Lima
Country
Peru

12. IPD Sharing Statement

Learn more about this trial

TELI COM - Telithromycin in Children With Otitis Media

We'll reach out to this number within 24 hrs